PD-L1 TPS I50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients

被引：0
|
作者：
Seo, J. [1 ]
Keam, B. [1 ]
Youk, J. [1 ]
Kim, M. [1 ]
Kim, T. M. [1 ]
Kim, D-W. [1 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1491P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The Percentage of PD-L1 Besides 50% Positivity Predicts Objective Response to Pembrolizumab in Non-Small Cell Lung Cancer
    Poma, A.
    Pasquini, G.
    Bruno, R.
    Ali, G.
    Proietti, A.
    Pecora, I.
    Petrini, L.
    Vasile, E.
    Chella, A.
    Fontanini, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S466 - S467
  • [22] Clinical impact of proton pump inhibitor on the therapeutic outcome of non-small cell lung cancer patients with PD-L1 TPS I50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor plus chemotherapy: A retrospective multicenter cohort study
    Kawachi, H.
    Yamada, T.
    Tamiya, M.
    Negi, Y.
    Goto, Y.
    Nakao, A.
    Shiotsu, S.
    Tanimura, K.
    Takeda, T.
    Okada, A.
    Harada, T.
    Date, K.
    Chihara, Y.
    Hasegawa, I.
    Tamiya, N.
    Iwasaku, M.
    Tokuda, S.
    Kijima, T.
    Takayama, K.
    ANNALS OF ONCOLOGY, 2023, 34
  • [23] Increased Antitumor Response to Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
    Park, S. E.
    Kim, Y.
    Kim, H. K.
    Lee, H.
    Cho, J. H.
    Lim, S. W.
    Lee, S.
    Ahn, J. S.
    Park, K.
    Ahn, M.
    Sun, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2425 - S2425
  • [24] Combination of plasma MMPs and PD-1-binding soluble PD-L1 predicts recurrence in gastric cancer and the efficacy of immune checkpoint inhibitors in non-small cell lung cancer
    Ando, Fumihiko
    Kashiwada, Takeru
    Kuroda, Shoko
    Fujii, Takenori
    Takano, Ryotaro
    Miyabe, Yoshishige
    Kunugi, Shinobu
    Sakatani, Takashi
    Miyanaga, Akihiko
    Asatsuma-Okumura, Tomoko
    Hashiguchi, Masaaki
    Kanazawa, Yoshikazu
    Ohashi, Ryuji
    Yoshida, Hiroshi
    Seike, Masahiro
    Gemma, Akihiko
    Iwai, Yoshiko
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] VALIDATION OF PD-L1 DYNAMIC EXPRESSION ON EXTRACELLULAR VESICLES AS A PREDICTOR OF RESPONSE TO IMMUNE-CHECKPOINT INHIBITORS AND SURVIVAL IN NON-SMALL CELL LUNG CANCER PATIENTS
    de Miguel Perez, Diego
    Barron, Feliciano
    Russo, Alessandro
    Lara-Mejia, Luis
    Gunasekaran, Muthukumar
    Cardona, Andres
    Peterson, Christine
    Colen, Rivka
    Naing, Aung
    Mack, Philip
    Hirsch, Fred
    Adamo, Vincenzo
    Arrieta, Oscar
    Rolfo, Christian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A25 - A26
  • [26] Serum immune checkpoint biomarkers as predictors of response to anti-PD-1/PD-L1 treatment in non-small cell lung cancer (NSCLC) patients
    Raza, A.
    Mohsin, R.
    Kanbour, A.
    Vijayakar, S.
    Philip, A.
    Tauro, M. A.
    Sherif, S.
    Merhi, M.
    Inchakalody, V.
    Gul, A. R. Zar
    Al Homsi, M. U.
    Dermime, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1380 - S1380
  • [27] Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
    Shao, Min-min
    Xu, Yue-ping
    Zhang, Jin-jing
    Mao, Mao
    Wang, Meng-chuan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (06): : 1446 - 1458
  • [28] Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
    Mussafi, Ofek
    Mei, Jie
    Mao, Wenjun
    Wan, Yuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [29] Advanced non-small cell lung cancer: the role of PD-L1 inhibitors
    Heigener, David F.
    Reck, Martin
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1468 - S1473
  • [30] Examination of PD-L1 and MHC Class I Expression in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
    Moore, Margaret
    Mills, Anne
    John, Melson
    Hall, Richard
    Gentzler, Ryan
    Stelow, Edward
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1126 - 1127
12345